Cytomegalovirus (CMV) Clinical Trial
Official title:
Post Authorization Study to Monitor Efficacy, Effectiveness, and Safety of Maribavir (LIVTENCITY®) in Adult Patients With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
The main aim of this study is to learn about the safety of Maribavir in adults with post-transplant cytomegalovirus (CMV) infection in routine clinical practice in Argentina. The other aim is to study the effectiveness of the treatment with Maribavir in routine clinical practice in Argentina. Participants will be treated by their doctors according to normal medical practice. Study data will be collected either from information already available in the medical records or during study conduct.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05319353 -
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection
|
Phase 3 | |
| Completed |
NCT05571137 -
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
|
||
| Not yet recruiting |
NCT06243731 -
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
|
||
| Not yet recruiting |
NCT06439342 -
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
|
Phase 3 | |
| Completed |
NCT05576805 -
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
|
||
| Completed |
NCT02775240 -
Study of SHP620 (Maribavir) in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01611974 -
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
|
Phase 2 | |
| Completed |
NCT05137717 -
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
|
Phase 3 | |
| Completed |
NCT02931539 -
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
|
Phase 3 | |
| Completed |
NCT02927067 -
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
|
Phase 3 |